Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer

• Published in: JNCI : Journal of the National Cancer Institute 2019-08, Vol.111 (8), p.867-871
• Main Authors: Kim, Rim S, Song, Nan, Gavin, Patrick G, Salgado, Roberto, Bandos, Hanna, Kos, Zuzana, Floris, Giuseppe, Eynden, Gert G G M Van den, Badve, Sunil, Demaria, Sandra, Rastogi, Priya, Fehrenbacher, Louis, Mamounas, Eleftherios P, Swain, Sandra M, Wickerham, D Lawrence, Costantino, Joseph P, Paik, Soonmyung, Wolmark, Norman, Geyer, Charles E, Lucas, Peter C, Pogue-Geile, Katherine L
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers; Biomarkers, Tumor - genetics; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Brief Communication; Chemotherapy; Chemotherapy, Adjuvant - adverse effects; Class I Phosphatidylinositol 3-Kinases - genetics; Confidence intervals; Disease-Free Survival; ErbB-2 protein; Fc receptors; Female; Health risks; Humans; Intestine; Lymphocytes; Lymphocytes, Tumor-Infiltrating - drug effects; Middle Aged; Monoclonal antibodies; Mutation; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - pathology; Oncology; Prediction models; Proportional Hazards Models; Pyrimidines - therapeutic use; Receptor, ErbB-2 - genetics; Receptors, IgG - genetics; Stromal Cells - drug effects; Stromal Cells - pathology; Targeted cancer therapy; Trastuzumab; Trastuzumab - adverse effects; Trastuzumab - therapeutic use; Tumor-infiltrating lymphocytes; Tumors
• ISSN: 0027-8874; 1460-2105
• DOI: 10.1093/jnci/djz032

Abstract We retrospectively assessed association of stromal tumor-infiltrating lymphocytes (sTILs) with clinical outcomes and molecular variables reportedly predictive of trastuzumab-benefit in National Surgical Adjuvant Breast and Bowel Project B-31 (N = 2130). sTILs were assessed in 1581 eligible B-31 cases utilizing all available hematoxylin and eosin slides. Mean concordance between main reviewer and six other pathologists was 90.8% in 100 cases. Cox regressions were used to calculate hazard ratios (HRs). In chemotherapy and trastuzumab added to chemotherapy arms, increases in sTILs, as a semicontinuous variable (combined arms HR = 0.42, 95% confidence interval = 0.27 to 0.64, two-sided P